We next aimed to test whether the US treatment enhanced delivery of IGF1, a neurotrophic factor that does not normally cross the BBB or BSCB,40 and could increase survival in our ALS mouse model. This evidence concerns the gene IGF1 and amyotrophic lateral sclerosis.